Quality Culture Revisited: Human Behavior as the Missing Link in Pharmaceutical Quality Management Systems.

Q3 Medicine
George Hove
{"title":"Quality Culture Revisited: Human Behavior as the Missing Link in Pharmaceutical Quality Management Systems.","authors":"George Hove","doi":"10.5731/pdajpst.2026-000018.1","DOIUrl":null,"url":null,"abstract":"<p><p>Pharmaceutical Quality Systems (PQS) based on ICH Q10 provide a formal framework for quality management, yet persistent quality failures, data integrity concerns, and regulatory observations indicate that structural compliance alone does not ensure effective performance. This narrative synthesis examines how human behavior contributes to PQS effectiveness and proposes that quality culture can be understood as the behavioral infrastructure through which PQS is enacted in practice.Through safety science, decision theory, organizational culture research, and published FDA Quality Management Maturity (QMM) materials, this paper explores how cognitive bias, normalization of deviance, psychological safety, and leadership signals influence core PQS elements, including process monitoring, deviation and CAPA management, change control, and management review. The synthesis proposes that differences in behavioral maturity may help explain why sites with comparable structural systems achieve different outcomes, while recognizing that this relationship is shaped by context, workload, incentives, and governance.A people‑systems model is introduced to describe how culture, behavior, and PQS structure interact to support sustained control and learning. The paper outlines practical implications for organizations seeking to strengthen behavioral indicators of PQS performance and suggests potential enhancements to regulatory inspection approaches, in which regulators interpret adaptive capacity and behavioral maturity primarily through objective evidence (for example, investigation depth, management review outputs, and CAPA effectiveness) alongside existing structural checks.</p>","PeriodicalId":19986,"journal":{"name":"PDA Journal of Pharmaceutical Science and Technology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PDA Journal of Pharmaceutical Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5731/pdajpst.2026-000018.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Pharmaceutical Quality Systems (PQS) based on ICH Q10 provide a formal framework for quality management, yet persistent quality failures, data integrity concerns, and regulatory observations indicate that structural compliance alone does not ensure effective performance. This narrative synthesis examines how human behavior contributes to PQS effectiveness and proposes that quality culture can be understood as the behavioral infrastructure through which PQS is enacted in practice.Through safety science, decision theory, organizational culture research, and published FDA Quality Management Maturity (QMM) materials, this paper explores how cognitive bias, normalization of deviance, psychological safety, and leadership signals influence core PQS elements, including process monitoring, deviation and CAPA management, change control, and management review. The synthesis proposes that differences in behavioral maturity may help explain why sites with comparable structural systems achieve different outcomes, while recognizing that this relationship is shaped by context, workload, incentives, and governance.A people‑systems model is introduced to describe how culture, behavior, and PQS structure interact to support sustained control and learning. The paper outlines practical implications for organizations seeking to strengthen behavioral indicators of PQS performance and suggests potential enhancements to regulatory inspection approaches, in which regulators interpret adaptive capacity and behavioral maturity primarily through objective evidence (for example, investigation depth, management review outputs, and CAPA effectiveness) alongside existing structural checks.

质量文化重访:作为药品质量管理体系缺失环节的人的行为。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
34
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书